Given these findings, NKCC1 inhibition could potentially be used in the clinic to improve glioblastoma treatment, given that Bumetanide (a commonly used diuretic, FDA-approved) decreases the invasive potential of glioma cells in vivo [13]. This evidence concerns the gene SLC12A2 and glioblastoma.